Spectromics: First Venture Capital Financing Round Concluded
Spectromics, the developer of rapid diagnostics to guide effective antibiotic treatment and reduce escalation of antibiotic resistance, has concluded its first Venture Capital financing round.
New Wave Ventures, a UK based Venture Capital investor has led the financing round that will provide the necessary funds to optimise and fully characterise this novel technology that promises to control how antibiotic stewardship will be managed at the point-of-prescription.
Spectromics was formed in April 2014 as a spin out from The University of Manchester. The founding scientists: Professor Roy Goodacre, of Manchester Institute of Biotechnology and Dr Mat Upton, of the School of Biomedical and Healthcare Sciences, Plymouth University, have worked on this technology for a number of years prior to company formation, they are now both Directors of the company.
Co-investor Professor Douglas Kell, Research Chair of Bioanalytical Sciences, The University of Manchester and past Chief Executive of the BBSRC said “As a microbiologist that has worked in the area of rapid diagnostics of complex systems for most of my career, and as a Founding Director of Aber Instruments (a company specialising in real-time biomass detection), I am impressed by the speed of this phenotypic test and from the data seen to date I believe it will be able to change how we select antimicrobials for effective treatment of individual infections.”
For more information, please see the Spectromics Press Release.